Teracorte Use In Pregnancy & Lactation

Use in pregnancy: Pregnancy category C.
Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.
Desoximetasone has been shown to be teratogenic and embryotoxic in mice, rats, and rabbits when given by subcutaneous or dermal routes of administration in doses 3 to 30 times the human dose of desoximetasone cream 0.25%. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, desoximetasone cream 0.25% should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. Drug of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.
Lactation: It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have deleterious effect on the infant. Nevertheless, exercise caution when desoximetasone is administered to a nursing woman.